Navigation Links
Almac Continues Biocatalysis Business Growth With a Further $4m R&D Investment
Date:10/7/2010

Almac Continues Biocatalysis Business Growth With a Further $4m R&D Investment -- CRAIGAVON, Northern Ireland, October 7, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, Financing Agreements Click to view news release full screen  

Almac Continues Biocatalysis Business Growth With a Further $4m R&D Investment

 

CRAIGAVON, Northern Ireland, October 7, 2010 /PRNewswire/ -- The need for green, economic, robust and scaleable processes for the synthesis of chiral APIs and intermediates prompted Almac (CPHI Booth 4F32) to build and fully integrate a biocatalysis group into its service portfolio. Last year Almac launched carbonyl reductase, transaminase, hydrolase, nitrilase, and nitrile hydratase enzyme screening kits and is continuing to both advance the biocatalysis business - and to broaden application of its biocatalysis expertise with a further $4m R&D investment.

The investment will be used primarily to focus around discovery of new biocatalytic platforms that can be rapidly implemented and scaled delivering cost effective processes to chiral intermediates. Other areas of research will investigate hyper-activation of biocatalysts reducing enzyme loadings, as well as development of efficient and robust drivers for cofactor recycle and problems with equilibriums.

As anticipated, the business has advanced from the sale of enzyme screening kits, then to screening and optimising custom transformations, and finally to the supply of 10s then 100s of kgs of chiral intermediates.

For example, preliminary screening was carried out to demonstrate that a carbonyl reductase (CRED) bioreduction could replace a resolution for the preparation of a chiral alcohol. Having identified a CRED at small scale, Almac prepared a hundred grams of the chiral alcohol and integrated it into the API process development programme.

The next step was to manufacture 30 kgs for incorporation into the GMP API manufacture for Phase I clinical trials.

The rapid scale-up from biocatalyst screening has been the critical success factor for the recent paradigm shift to bioprocessing acceptance for the synthesis of APIs and fine chemicals.

"The biocatalyst is now Almac's first choice for scale-up chemistry involving chirality as it provides efficient, clean and robust processes. The $4m R&D investment demonstrates Almac's continued commitment to biocatalysis, supporting further growth in our expertise and capabilities in biotechnology", notes Head of Biocatalysis, Dr. Tom Moody.

"Clean-up" application:

The latest addition to the application of Almac biocatalysis expertise is for the "clean-up" of chemical reactions (Moody, T. Pharma Chem, April/May edition, 36-38, 2010). Impurities produced in multi-step processes are often difficult to remove, particularly if they are similar in structure to the desired product. When crystallisation or partition does not provide sufficient purity, Almac has used a biocatalytic process to selectively modify impurities. The impurities are then sufficiently different in physical properties from the desired product that they can be removed using conventional separation techniques.

"Biocatalysis provides a mild, regio & chemoselective process to modify impurities, thus altering their physical properties to facilitate their removal", says Tom Moody.

Notes to Editors

About Almac Group

The Almac Group comprises five closely integrated divisions offering a broad range of services from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply and IXRS technology (IVRS/IWRS), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors.

The company employs over 2,800 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California. Almac has officially gained full possession of its new $120m North American Headquarters, which started in July 2008, and employees will relocate during the fall.

For more information on Almac, please visit http://www.almacgroup.com


'/>"/>
SOURCE Almac Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Almac Launch Biomarkers for Biopharma
2. Almacs Clinical Technologies Division Undergoes Successful Joint GCP-GMP MHRA Inspection
3. Almacs North American Headquarters Opens its Doors for Audits
4. Adult Smoking Rate Continues Downward Trend
5. Gilbert Hospital Continues Cutting Edge Treatments
6. The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement
7. Bone Mineral Content Continues to Increase in Obese Adolescents During Weight Loss
8. Phase I and Phase I/II DCVax(R)-Brain Data Continues to Show Significantly Improved Survival Rates for Brain Cancer Patients
9. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
10. Carpet One Floor & Home Continues Making Dramatic Strides in Funding Breast Cancer Research and Awareness
11. Medarex Announces Ipilimumab Program Continues to Move Forward
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... -- Endo International plc (NASDAQ: ENDP ) ... , President, U.S. Branded Pharmaceuticals, has decided to ... of a successor. Mr. Lortie joined Endo in ... responsibility for all strategic, commercial and operational functions, ... commercial operations, managed markets, manufacturing, supply chain and ...
(Date:5/5/2016)... ORANGE COUNTY, Calif. , May 5, 2016 ... for nearly a decade due to concerns that ... advances in the approach to imaging, as well ... in a new era of medical peripherals that ... better care.   Ampronix  advanced medical imaging is a ...
(Date:5/5/2016)... , May 5, 2016 /PRNewswire/ ... announced the addition of the  "Europe ... - 2016"  report to their offering.  ... ) , ,The latest research ... Highlights - 2016, provides comprehensive insights ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... May 06, 2016 , ... DrugDev President and CEO ... the pharmaceutical industry conducts clinical trials. This month Ibs was named No. 20 on ... and he was honored as a Tech Disruptor by the Philadelphia Business Journal. , ...
(Date:5/6/2016)... ... 06, 2016 , ... Featured cast and producers of the ... at the 2016 Learning Summit , June 12-15, in Paradise Valley, Arizona. ... stories—of complicated family issues, financial difficulties, and other personal obstacles—are the stories of ...
(Date:5/6/2016)... ... May 06, 2016 , ... A wide variety of national pet product manufacturers, companies and ... Safety Media Showcase Wednesday, May 18 from noon to 8 p.m. at New York City’s ... at new and established home, garden, outdoor and safety pet products in today’s marketplace. ...
(Date:5/6/2016)... ... May 06, 2016 , ... ... an upcoming episode, airing third quarter 2016, via Discovery Channel. Dates and show ... a leader in optimized drug discovery through innovative cellular analysis. In this segment, ...
(Date:5/6/2016)... ... May 06, 2016 , ... Logically, spring weather, with its moderate ... weather is too cold, dry or hot, water on the eye surface can evaporate, ... from the surrounding air. There’s only one problem, according to radio show and water ...
Breaking Medicine News(10 mins):